Episode Details
Back to Episodes
Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data
Published 5 months ago
Description
He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy.